All News

1 March 2010

GTC Provides Update on TG20 Monoclonal Antibody Targeting CD20Antibodies

24 February 2010

Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System’s Ability to Destroy Anthrax BacteriaAntibodies

24 February 2010

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian CancerAntibodies

22 February 2010

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung CancerAntibodies

22 February 2010

Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary EndpointAntibodies

18 February 2010

VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular EdemaAntibodies

18 February 2010

FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult LeukemiaAntibodies

16 February 2010

Thallion Pharmaceuticals and LFB biotechnologies sign definitive agreement to develop and commercialize treatment for E. Coli (STEC) infectionAntibodies

16 February 2010

New High Purity Immunoglobulin Enters Phase III in Europe and the USAntibodies

11 February 2010

ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATEAntibodies

10 February 2010

Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D DayAntibodies

9 February 2010

Phase I Trial Commences Treating Patients with Pancreatic and Colorectal Cancer Using Novel Monoclonal AntibodyAntibodies

9 February 2010

XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes PatientsAntibodies

9 February 2010

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone MetastasesAntibodies

8 February 2010

Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and RocheAntibodies

8 February 2010

AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc.Antibodies

5 February 2010

TenX Biopharma Licenses Zanolimumab From GenmabAntibodies

4 February 2010

BTG Receives First European Regulatory Approval for DigiFabAntibodies

3 February 2010

Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin LymphomaAntibodies

2 February 2010

Cambridge-Based Biotech Isogenica Announces New Partnership with PhylogicaAntibodies

2 February 2010

Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for CancerAntibodies

2 February 2010

Compugen Discovers Novel Protein for Treatment of Autoimmune DiseasesAntibodies

29 January 2010

Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancerAntibodies

29 January 2010

Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option FundAntibodies

28 January 2010

Pacgen Signs Research Collaboration AgreementsAntibodies

28 January 2010

Patrys to work with CSL to explore antibody drugsAntibodies

27 January 2010

MorphoSys Licenses HuCAL PLATINUM Antibody Library to Shionogi in Research PartnershipAntibodies

26 January 2010

European Commission Approves ORENCIA (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA)Antibodies

26 January 2010

YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USAAntibodies

25 January 2010

ASCO-GI: Overall Survival With Erbitux Is Significantly Improved in Patients With KRAS Wild-Type Tumors in CRYSTALAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

c-Met-Targeted Antibody Therapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

PSMA-Targeted Therapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Mesothelin-Targeted Immunotherapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review